Cargando…

Second primary malignancy after radical prostatectomy in a cohort from the Middle East

BACKGROUND: Data from the Middle East regarding second primary malignancy (SPM) after radical prostatectomy are limited. Our objective was to estimate the overall risk of developing second primary malignancy (SPM) among Middle Eastern men with prostate cancer who underwent surgical extirpation of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahait, Mohammed, Mukherji, Deborah, Hamieh, Nadine, Nassif, Samer, Jabbour, Mark, Khauli, Raja, Bulbul, Muhammad, Abou kheir, Wassim, El Hajj, Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Pacific Prostate Society 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004622/
https://www.ncbi.nlm.nih.gov/pubmed/29922631
http://dx.doi.org/10.1016/j.prnil.2017.09.002
_version_ 1783332551417397248
author Shahait, Mohammed
Mukherji, Deborah
Hamieh, Nadine
Nassif, Samer
Jabbour, Mark
Khauli, Raja
Bulbul, Muhammad
Abou kheir, Wassim
El Hajj, Albert
author_facet Shahait, Mohammed
Mukherji, Deborah
Hamieh, Nadine
Nassif, Samer
Jabbour, Mark
Khauli, Raja
Bulbul, Muhammad
Abou kheir, Wassim
El Hajj, Albert
author_sort Shahait, Mohammed
collection PubMed
description BACKGROUND: Data from the Middle East regarding second primary malignancy (SPM) after radical prostatectomy are limited. Our objective was to estimate the overall risk of developing second primary malignancy (SPM) among Middle Eastern men with prostate cancer who underwent surgical extirpation of their prostate. MATERIALS AND METHODS: We conducted a retrospective study of 406 patients who underwent radical prostatectomy in a tertiary centre and who had no evidence of previous malignancy from 1998 to 2012. Standardized incidence ratios (SIRs) and 95% confidence interval (CI) were calculated to analyze the risk of SPM in our population compared with the general population. Cox-regression models were also conducted to correlate the clinicopathological factors with the development of SPM. RESULTS: After 14 years of follow-up, the incidence rate of SPM was 100.9 per 1,000 person-years. The most frequent SPMs were bladder cancer (n = 11, 27%) followed by hematological malignancies (n = 9, 22%) and lung cancer (n = 7, 17%). The overall risk for men with prostate cancer to develop SPM is lower than the men in the general population (standardized incidence ratios = 0.19; 95% CI: 0.14–0.25). A multivariate analysis failed to correlate any of the clinicopathological factors with the development of SPM. CONCLUSION: Patients with prostate cancer who underwent surgical expiration of their prostate are at lower risk of developing SPM compared with the general population.
format Online
Article
Text
id pubmed-6004622
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Asian Pacific Prostate Society
record_format MEDLINE/PubMed
spelling pubmed-60046222018-06-19 Second primary malignancy after radical prostatectomy in a cohort from the Middle East Shahait, Mohammed Mukherji, Deborah Hamieh, Nadine Nassif, Samer Jabbour, Mark Khauli, Raja Bulbul, Muhammad Abou kheir, Wassim El Hajj, Albert Prostate Int Original Article BACKGROUND: Data from the Middle East regarding second primary malignancy (SPM) after radical prostatectomy are limited. Our objective was to estimate the overall risk of developing second primary malignancy (SPM) among Middle Eastern men with prostate cancer who underwent surgical extirpation of their prostate. MATERIALS AND METHODS: We conducted a retrospective study of 406 patients who underwent radical prostatectomy in a tertiary centre and who had no evidence of previous malignancy from 1998 to 2012. Standardized incidence ratios (SIRs) and 95% confidence interval (CI) were calculated to analyze the risk of SPM in our population compared with the general population. Cox-regression models were also conducted to correlate the clinicopathological factors with the development of SPM. RESULTS: After 14 years of follow-up, the incidence rate of SPM was 100.9 per 1,000 person-years. The most frequent SPMs were bladder cancer (n = 11, 27%) followed by hematological malignancies (n = 9, 22%) and lung cancer (n = 7, 17%). The overall risk for men with prostate cancer to develop SPM is lower than the men in the general population (standardized incidence ratios = 0.19; 95% CI: 0.14–0.25). A multivariate analysis failed to correlate any of the clinicopathological factors with the development of SPM. CONCLUSION: Patients with prostate cancer who underwent surgical expiration of their prostate are at lower risk of developing SPM compared with the general population. Asian Pacific Prostate Society 2018-06 2017-09-30 /pmc/articles/PMC6004622/ /pubmed/29922631 http://dx.doi.org/10.1016/j.prnil.2017.09.002 Text en © 2017 Asian Pacific Prostate Society, Published by Elsevier Korea LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Shahait, Mohammed
Mukherji, Deborah
Hamieh, Nadine
Nassif, Samer
Jabbour, Mark
Khauli, Raja
Bulbul, Muhammad
Abou kheir, Wassim
El Hajj, Albert
Second primary malignancy after radical prostatectomy in a cohort from the Middle East
title Second primary malignancy after radical prostatectomy in a cohort from the Middle East
title_full Second primary malignancy after radical prostatectomy in a cohort from the Middle East
title_fullStr Second primary malignancy after radical prostatectomy in a cohort from the Middle East
title_full_unstemmed Second primary malignancy after radical prostatectomy in a cohort from the Middle East
title_short Second primary malignancy after radical prostatectomy in a cohort from the Middle East
title_sort second primary malignancy after radical prostatectomy in a cohort from the middle east
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004622/
https://www.ncbi.nlm.nih.gov/pubmed/29922631
http://dx.doi.org/10.1016/j.prnil.2017.09.002
work_keys_str_mv AT shahaitmohammed secondprimarymalignancyafterradicalprostatectomyinacohortfromthemiddleeast
AT mukherjideborah secondprimarymalignancyafterradicalprostatectomyinacohortfromthemiddleeast
AT hamiehnadine secondprimarymalignancyafterradicalprostatectomyinacohortfromthemiddleeast
AT nassifsamer secondprimarymalignancyafterradicalprostatectomyinacohortfromthemiddleeast
AT jabbourmark secondprimarymalignancyafterradicalprostatectomyinacohortfromthemiddleeast
AT khauliraja secondprimarymalignancyafterradicalprostatectomyinacohortfromthemiddleeast
AT bulbulmuhammad secondprimarymalignancyafterradicalprostatectomyinacohortfromthemiddleeast
AT aboukheirwassim secondprimarymalignancyafterradicalprostatectomyinacohortfromthemiddleeast
AT elhajjalbert secondprimarymalignancyafterradicalprostatectomyinacohortfromthemiddleeast